Transgene SA at Combined General Meeting held on May 25, 2022, approved the Appointment of three new Directors: Dr. Alessandro Riva, MD, and Prof. Jean-Yves Blay, MD, PhD, as independent Directors, and Laurence Espinasse as non-independent Director; Separation of the roles of Chairman and Chief Executive Officer, appointing Dr. Alessandro Riva, MD, as independent Chairman of the Board, alongside Hedi Ben Brahim who continues as Chief Executive Officer; Establishment of an Environmental, Social and Governance (ESG) committee comprised of Sandrine Flory (committee Chair), Marie Landel and Hedi Ben Brahim. This new committee aims to enhance the Company's ESG performance and reinforce sustainability in the Company's strategy. Dr. Alessandro Riva, MD, independent Director and non-executive Chairman: Dr. Riva has nearly 30 years' experience in the Life Sciences industry and is currently CEO of Intima Bioscience which specializes in cell therapies for solid cancers.

Prior to this role, he served as CEO of Ichnos Sciences and Executive Vice President (EVP), Global Head of Oncology Therapeutics and Cell & Gene Therapy at Gilead Sciences, where he was instrumental in the acquisition of Kite Pharma and led its integration and growth. He also managed the US and EU approvals of Yescarta, the first approved CAR-T cell therapy for adult patients with diffuse large B cell lymphoma. Prior to Gilead, Dr. Riva was EVP, Global Head of Oncology Development and Medical Affairs at Novartis Pharmaceuticals.

He was President ad interim of Novartis Oncology during the acquisition of GSK Oncology. Dr. Riva currently serves on the Boards of Beigene and Century Therapeutics. He received his bachelor's degree in medicine and surgery from the University of Milan and a certificate board in oncology and hematology from the same institution.

Prof. Jean-Yves Blay, MD, PhD, independent Director: Jean-Yves Blay is Professor of Medical Oncology and has been General Director of the Léon Bérard Center in Lyon since 2014. He holds a PhD obtained in 1994 from the Claude Bernard University in Lyon and has been authorized to supervise research since 1996. He currently leads the LYriCAN project (integrated cancer research) at the French National Cancer Institute.

Former president of the European Organization for Research and Treatment of Cancer, Prof. Jean-Yves Blay is currently director of the NETSARC network accredited by the French National Cancer Institute and president of the French Sarcoma Group. At international level, he is a faculty member of the ESMO (European Society of Medical Oncology) and the SPH (Scientific Panel for Health). He has led the European Commission's Conticanet network and is currently leading the Eurosarc FP7 project.

Author of more than 500 international publications, Prof. Jean-Yves Blay advises various national and international research organizations and institutions. His work has been rewarded by several prizes including that of the French National Academy of Medicine, which he joined as a corresponding member in 2014. Laurence Espinasse, Director: Laurence Espinasse has been the Legal Director of Institut Mérieux since 2021.

She practiced as a lawyer for more than 15 years in the law firm MDL, of which she was a partner. Laurence Espinasse also practiced at Ernst & Young where she was involved in complex legal transactions, such as M&A and Restructuring, and was appointed Mission Director from 2012 to 2013. Laurence Espinasse obtained her Professional Lawyer's Certificate (Business Law) at the École des avocats Centre Sud (Montpellier, France).